We provide lab-to-market services to pharmaceutical companies to satisfy the demand for novel drug delivery systems, and innovative and efficient treatments.
We provide lab-to-market services to pharmaceutical companies to satisfy the demand for novel drug delivery systems, and innovative and efficient treatments.
The success of drug therapies is largely influenced by the use of drug delivery systems that are adequate and efficient. Our microencapsulation technology offers great potential for the pharmaceutical industry. In addition to overcoming some of the problems of conventional therapy, our advanced microencapsulation technology enhances therapeutic drug efficacy by introducing timed and targeted drug release.
Slow-release drugs are not new to the market. But we are moving a step forward. We are pioneering programmed-shell microcapsules with a controlled release function, a new way to deliver drugs. We optimise the efficiency of existing drugs by using innovative and high-performing drug delivery systems.
Possessing unique microencapsulation capabilities, we can precisely programme the release time of drugs, achieving efficacy at an entirely different level. Our advanced microencapsulation technology is the only one on the market which produces programmed-shell microcapsules that can release drugs according to predefined scenarios:
Our advanced microencapsulation technology is the only one on the market which produces programmed-shell microcapsules with a complex shell design that can open and release active substances according to predefined scenarios:
We programme the microcapsules’ shells to release active substances with high precision (release at a specific time of the day).
We can programme the microcapsules’ shells to ensure the constant and prolonged release of active compounds over a long period of time, up to several months.
Active substances can be released slowly or immediately.
Active compounds are released under certain circumstances (release on demand). The microcapsule opening can be triggered by environmental conditions (change in temperature or pH), mechanical action (friction and other forces) or external stimuli (ultrasound, UV light).
The time and targeted release functions result in improved efficacy of the drug, prolonged action, and optimal dosage.
Controlled drug release is a reliable means to deliver drugs to the target site in a sustained controlled release manner to obtain optimum benefits and maintain the desired concentration without side effects. We deliver drugs into the body at the right time, at the right dosage and at the right place.
Microencapsulation is a useful tool to reduce off-target effects that can lead to side effects ranging in severity from mild to life-threatening. Drugs can also be delivered in smaller dosages due to less drug waste on incorrect targets.
Today, different methods have been applied for drug delivery. However, the widespread emulsion spray-drying and microemulsification techniques produce emulsion microdroplets with no shells, meaning they are not microcapsules. The lack of shells makes the controlled and timed release impossible. The emulsification process also limits the selection of active substances. While liposomes and microfluidic solutions are more advanced options, liposomes are highly unstable and expensive, and microfluidics is a costly technique and low yield, making it limited mainly to research purposes.
We can encapsulate practically any active substance, liquid or solid, including small molecules and microelements.
We can choose from a wide range of FDA-approved biocompatible and biodegradable polymers. Our microcapsules can satisfy the specific needs of vegetarians and vegans.
Unlike liposomes and emulsion droplets, our microcapsules are highly stable, making our technology suitable for a wide range of applications.
Our microcapsules can hold high volumes of ingredients (cargo-shell ratio up to 10:1).
Our advanced microencapsulation technology has great potential for target delivery of anticancer drugs to tumours.
Vincristine, an anticancer drug, is known for its increased cellular toxicity, which results in multiple side effects. The targeted delivery of vincristine and other chemotherapeutic drugs to tumours will help reduce its side effects. The most efficient way is using stem cells as carriers to deliver the drugs to tumours. However, given the cytotoxicity of vincristine and other similar drugs, this solution is not optimal.
The microencapsulation of vincristine and other anticancer drugs solves this problem. The microencapsulated vincristine can be safely captured by stem cells and delivered to tumours through cancer migration pathways. When stem cells carrying the microencapsulated vincristine come into contact with cancer cells, vincristine is released from the microcapsules causing the cancer cells’ death.
Drug delivery to cancer cells
Loading human mesenchymal stem cells (hMSCs) with silica-coated multi-layered PSS/PAH microcapsules containing vincristine allows targeted drug delivery to tumours.
Loading human mesenchymal stem cells (hMSCs) with microcapsules
Silica-coated multi-layered PSS/PAH microcapsules (left) containing a drug (middle, in red) are engulfed by human mesenchymal stem cells (right).
References:
“Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers” 2019, Applied Materials & Interfaces (10.1021/acsami.8b22685)
Link: https://pubs.acs.org/doi/10.1021/acsami.8b22685
We are looking for partnerships with pharmaceutical companies to co-develop and co-promote our novel controlled drug delivery mechanism to bring treatment effectiveness to the next level.